相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
Tina Vilsboll et al.
DIABETES OBESITY & METABOLISM (2019)
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
Athena Philis-Tsimikas et al.
DIABETES OBESITY & METABOLISM (2019)
Use of IDegLira Is Associated with High Persistency Rates Up to 12 Months (M) and Improved A1C after 6M in Swedish Clinical Practice
Bjorn Eliasson et al.
DIABETES (2019)
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
Vanita R. Aroda et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Liana K. Billings et al.
DIABETES CARE (2018)
Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study
Hermione Price et al.
DIABETES OBESITY & METABOLISM (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic
David M. Williams et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2018)
Physicians' real-world experience with IDegLira: results of a European survey
Russell Drummond et al.
BMJ OPEN DIABETES RESEARCH & CARE (2018)
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial
H. W. Rodbard et al.
DIABETIC MEDICINE (2017)
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
Sultan Linjawi et al.
DIABETES THERAPY (2017)
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
Sultan Linjawi et al.
DIABETES THERAPY (2017)
Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center
Daniela Sofra
DIABETES THERAPY (2017)
Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center
Daniela Sofra
DIABETES THERAPY (2017)
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
Stewart B. Harris et al.
DIABETES OBESITY & METABOLISM (2017)
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes The DUAL V Randomized Clinical Trial
Ildiko Lingvay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
John B. Buse et al.
DIABETES CARE (2014)
Prevalence and Factors Associated With Resistant Hypertension in a Large Health Maintenance Organization in Israel
Dahlia Weitzman et al.
HYPERTENSION (2014)
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
Stephen C. L. Gough et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy of Liraglutide in a Real-Life Cohort
Anthony Heymann et al.
DIABETES THERAPY (2014)
The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization
Varda Shalev et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2011)
分享论文
